BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 25547524)

  • 1. Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?
    Antonarakis ES
    Expert Rev Anticancer Ther; 2015 Feb; 15(2):143-5. PubMed ID: 25547524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Zhu Y; Silberstein JL; Taylor MN; Maughan BL; Denmeade SR; Pienta KJ; Paller CJ; Carducci MA; Eisenberger MA; Luo J
    J Clin Oncol; 2017 Jul; 35(19):2149-2156. PubMed ID: 28384066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.
    Liu C; Armstrong C; Zhu Y; Lou W; Gao AC
    Oncotarget; 2016 May; 7(22):32210-20. PubMed ID: 27049719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide.
    Markowski MC; Frick KD; Eshleman JR; Luo J; Antonarakis ES
    Prostate; 2016 Dec; 76(16):1484-1490. PubMed ID: 27404039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent androgen receptor addiction in castration-resistant prostate cancer.
    Schweizer MT; Yu EY
    J Hematol Oncol; 2015 Nov; 8():128. PubMed ID: 26566796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).
    Penning TM
    J Steroid Biochem Mol Biol; 2015 Sep; 153():105-13. PubMed ID: 26032458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer.
    De Laere B; Rajan P; Grönberg H; Dirix L; Lindberg J;
    JAMA Oncol; 2019 Jul; 5(7):1060-1062. PubMed ID: 31046065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.
    Cao B; Qi Y; Zhang G; Xu D; Zhan Y; Alvarez X; Guo Z; Fu X; Plymate SR; Sartor O; Zhang H; Dong Y
    Oncotarget; 2014 Mar; 5(6):1646-56. PubMed ID: 24722067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer.
    Luo J
    Asian J Androl; 2016; 18(4):580-5. PubMed ID: 27174161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen pathway resistance in prostate cancer and therapeutic implications.
    Maughan BL; Antonarakis ES
    Expert Opin Pharmacother; 2015; 16(10):1521-37. PubMed ID: 26067250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation.
    Tummala R; Nadiminty N; Lou W; Evans CP; Gao AC
    Prostate; 2016 Apr; 76(5):445-55. PubMed ID: 26714839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.
    Antonarakis ES; Armstrong AJ; Dehm SM; Luo J
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):231-41. PubMed ID: 27184811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
    Kohli M; Ho Y; Hillman DW; Van Etten JL; Henzler C; Yang R; Sperger JM; Li Y; Tseng E; Hon T; Clark T; Tan W; Carlson RE; Wang L; Sicotte H; Thai H; Jimenez R; Huang H; Vedell PT; Eckloff BW; Quevedo JF; Pitot HC; Costello BA; Jen J; Wieben ED; Silverstein KAT; Lang JM; Wang L; Dehm SM
    Clin Cancer Res; 2017 Aug; 23(16):4704-4715. PubMed ID: 28473535
    [No Abstract]   [Full Text] [Related]  

  • 14. Developing a Novel Enzalutamide-Resistant Prostate Cancer Model via AR F877L Mutation in LNCaP Cells.
    Wang R; Ma S; Xu N; Gan Y; Li P; Zhang J; Zhang Z; Gu Q; Xiang J
    Curr Protoc; 2024 Apr; 4(4):e1033. PubMed ID: 38652202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects.
    Ferraldeschi R; Welti J; Luo J; Attard G; de Bono JS
    Oncogene; 2015 Apr; 34(14):1745-57. PubMed ID: 24837363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer.
    Ho Y; Dehm SM
    Endocrinology; 2017 Jun; 158(6):1533-1542. PubMed ID: 28368512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer.
    Cai L; Tsai YH; Wang P; Wang J; Li D; Fan H; Zhao Y; Bareja R; Lu R; Wilson EM; Sboner A; Whang YE; Zheng D; Parker JS; Earp HS; Wang GG
    Mol Cell; 2018 Oct; 72(2):341-354.e6. PubMed ID: 30270106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.
    Antonarakis ES; Chandhasin C; Osbourne E; Luo J; Sadar MD; Perabo F
    Oncologist; 2016 Dec; 21(12):1427-1435. PubMed ID: 27628492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer.
    Chism DD; De Silva D; Whang YE
    Expert Rev Anticancer Ther; 2014 Nov; 14(11):1369-78. PubMed ID: 24927631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance.
    Zhan Y; Zhang G; Wang X; Qi Y; Bai S; Li D; Ma T; Sartor O; Flemington EK; Zhang H; Lee P; Dong Y
    Mol Cancer Res; 2017 Jan; 15(1):59-68. PubMed ID: 27671337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.